arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Enveric Biosciences, Inc.

ENVB
$1.53 ▼ -0.04 (-2.55%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
58 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Enveric Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.3M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -25.5%
FCF / Share $-1.49
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

58-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.48M
↓ -7.3%
Net Income Profit after all expenses
$-1.63M
↑ +25.2%
Operating Margin Operating profit as % of sales
-13.2%
↑ +8.2%
FCF / Share Free cash flow per share
$-1.49
↓ -12.3%
Long-Term Debt Long-term obligations
$1.70K
↓ -99.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health
0
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 58 quarters